학술논문
Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients
Document Type
article
Author
Clovis A. Silva; Ana C. Medeiros-Ribeiro; Leonard V. K. Kupa; Emily F. N. Yuki; Sandra G. Pasoto; Carla G. S. Saad; Solange R. G. Fusco; Rosa M. R. Pereira; Samuel K. Shinjo; Ari S. R. Halpern; Eduardo F. Borba; Fernando H. C. Souza; Lissiane K. N. Guedes; Renata Miossi; Karina R. Bonfiglioli; Diogo S. Domiciano; Andrea Y. Shimabuco; Danieli C. O. Andrade; Luciana P. C. Seguro; Ricardo Fuller; Percival D. Sampaio-Barros; Ana P. L. Assad; Julio C. B. Moraes; Claudia Goldenstein-Schainberg; Henrique A. M. Giardini; Henrique C. Silva; Victor A. O. Martins; Lorena E. B. Villamarin; Renata S. Novellino; Lucas P. Sales; Carlo S. R. Araújo; Matheus S. R. Silva; Dilson M. N. Filho; Marta H. Lopes; Alberto J. S. Duarte; Esper G. Kallas; Nadia E. Aikawa; Eloisa Bonfa
Source
Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022)
Subject
Language
English
ISSN
2041-1723
Abstract
Characterising the response to SARS-CoV-2 post vaccination is critical in the appraisement of the induced immune response, performance and protective potential. Here the authors present data from a phase 4 clinical trial in autoimmune rheumatic disease patients 6 months post second dose of Sinovac-CoronaVac inactivated vaccine that show a marked reduction in antibody particularly in males or those under treatment with immune targeting therapies but saw no rise in COVID-19 disease.